Skip to main content
Scroll Top
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
News
Home
Alzheimer
Clinical Trials on Alzheimer’s Disease (CTAD CHINA)
Most Viewed Posts
Clear Filters
Challenges in developing Geroscience trials
19 August 2023
The RECOVERY study: first results of a pilot clinical trial to evaluate brain photobiomodulation in acute concussion in sportspeople
13 October 2023
Photobiomodulation: light to treat Alzheimer’s disease
2 July 2024
24 October 2023
Clinical Trials on Alzheimer’s Disease (CTAD CHINA)
Read the article
Jacques Touchon (MD, PhD), University of Montpellier and Guillaume Blivet (MPH), REGEnLIFE, France.
Share this article
alzheimer
Oral Communications
Post navigation
Previous post
The RECOVERY study: first results of a pilot clinical trial to evaluate brain photobiomodulation in acute concussion in sportspeople
Next post
Is brain photobiomodulation therapy safe and effective in treating sportspeople with acute concussion? First results of a pilot clinical trial (RECOVERY STUDY)
Get a Quote